No attachments available.
Preclinical PREVENT Cancer Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers
Contact and place of performance
Nicole Belanger
Not specified
Multiple Award IDIQ to the following contractors: HHSN261201500032I, The Research Institute of Fox Chase Cancer Center HHSN261201500041I, SRI International HHSN261201500042I, IIT Research Institute HHSN261201500018I, University of Texas MD Anderson Cancer Center HHSN261201500036I, University of Alabama at Birmingham HHSN261201500037I, Medical College of Wisconsin HHSN261201500038I, University of Oklahoma Health Sciences Center HHSN261201500039I, Weill Medical College of Cornell University
The National Cancer Institute issued an award notice for the Preclinical PREVENT Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. This requirement was finalized under solicitation number N01CN5500347 and is categorized under NAICS code 541711 and PSC code A. The notice was published on September 25, 2015, with Nicole Belanger serving as the point of contact.
The award is a multiple award Indefinite Delivery Indefinite Quantity (IDIQ) contract distributed among eight organizations. The participating contractors include The Research Institute of Fox Chase Cancer Center (HHSN261201500032I), SRI International (HHSN261201500041I), IIT Research Institute (HHSN261201500042I), and the University of Texas MD Anderson Cancer Center (HHSN261201500018I).
Other institutions selected for this multiple award IDIQ include the University of Alabama at Birmingham (HHSN261201500036I), Medical College of Wisconsin (HHSN261201500037I), University of Oklahoma Health Sciences Center (HHSN261201500038I), and Weill Medical College of Cornell University (HHSN261201500039I).
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.